Please Wait.....
Report
T-Cell therapy Market By Therapy Type (CAR T-Cell therapy, T-Cell Receptor (TCR)-Based), By Indication (Lymphoma, Acute Lymphocytic Leukemia, Others), By End User (Hospitals, Cancer Treatment Centers): Global Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2023-05-01 I 274 Pages I Allied Market Research
The T-cell therapy Market valued for $2,823.07 million in 2022 and is estimated to reach $15,182.30 million by 2032, exhibiting a CAGR of 18.3% from 2023 to 2032. T cells are a type of immune cell that plays a critical role in the body's defense against disease. T-cell therapy involves the manipulation of a patient's T cells outside the body, often using genetic engineering techniques, to enhance their ability to recognize and attack cancer cells or other disease-causing cells. These modified T cells are then infused back into the patient's body, where they can seek out and destroy cancer cells.
The T-cell therapy market is being driven by several key factors such as the increasing prevalence of cancer resulting in a greater demand for effective treatment options. T-cell therapy has emerged as a promising approach for treating cancer and other diseases including autoimmune disorders and viral infections, driving its adoption and growth. Additionally, the aging population is another factor that is driving the demand for T-cell therapies. The geriatric population is more prone to developing cancer and other diseases, creating a larger pool of potential patients for T-cell therapy. Furthermore, advances in biotechnology and genetic engineering have made it possible to develop more targeted and personalized T-cell therapies, which are likely to drive the market growth. These therapies have shown promising results in clinical trials, leading to increased investment in research and development activities.
Moreover, the rise in key strategies adopted by the key market players such as agreement, and collaborations further drives the growth of the market during the forecast period. For instance, on February 10, 2021, AbbVie and Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome editing biotechnology company, entered into a collaboration and license agreement for the research and development of chimeric antigen receptor (CAR)-T cell therapeutics. Furthermore, a rise in approvals from regulatory organizations is further providing opportunity for market growth. For instance, on October 17, 2022, Gilead Company, a biopharmaceutical company received the European Commission (EC) approval for the use of Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who relapse within 12 months from completion of, or are refractory to, first line chemoimmunotherapy. Thus, the adoption of such strategies by key manufacturers can potentially increase the demand and adoption of cell therapy technology and provide lucrative opportunity to market growth.
However, side effects associated with cellular therapies such as cytokine release syndrome and neurotoxicity, which can limit its use. Furthermore, the high cost of treatment is also a significant challenge for patients and healthcare providers and can limit the adoption of these therapies. These factors collectively have hindered the market growth to some extent.
The global T-cell therapy market is segmented into therapy type, indication, end user and region. As per therapy type, the market is categorized into CAR T-cell Therapy and T Cell Receptor (TCR)-Based. The CAR T-cell Therapy segment is further categorized by product type into Axicabtagene Ciloleucel, Tisagenlecleucel, Bexucabtagene Autoleucel and Others (Ciltacabtagene autoleucel, Lisocabtagene Maraleucel, Idecabtagene Vicleucel). According to indication, the market is segregated into Lymphoma, Acute Lymphocytic Leukemia, and Others (Multiple Myeloma, Melanoma). According to end user, the market is segregated into Hospitals and Cancer Treatment Centers. Region wise, the market is analyzed across North America (the U.S., Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China and rest of Asia-Pacific), and LAMEA (Latin America, Middle East & Africa).
Major key players that operate in the global T-cell therapy market are Novartis AG, Autolus Therapeutics, Caribou Biosciences, Inc, Gilead Sciences, Immunocore Ltd., Celyad Oncology, Cartesian Therapeutics, Inc., Johnson & Johnson, Bristol-Myers Squibb Company and Cellectis, Inc. The key players operating in the market have adopted product approval, agreement, and collaboration as their key strategies to expand their product portfolio.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the t-cell therapy market analysis from 2022 to 2032 to identify the prevailing t-cell therapy market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the t-cell therapy market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global t-cell therapy market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Therapy Type
- CAR T-Cell therapy
- Product Type
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
- T-Cell Receptor (TCR)-Based
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Others
By End User
- Hospitals
- Cancer Treatment Centers
By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle East And Africa
- Key Market Players
- Caribou Biosciences, Inc
- Celyad Oncology
- Gilead Sciences, Inc.
- Novartis AG
- Cellectis, Inc.
- Johnson & Johnson
- Autolus Therapeutics
- Bristol-Myers Squibb Company
- Immunocore Ltd.
- Cartesian Therapeutics, Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of cancer
3.4.1.2. Increase in demand of ideal therapeutics for treatment
3.4.1.3. Rise in awareness regarding T-cell therapy
3.4.2. Restraints
3.4.2.1. High cost of T-cell therapies
3.4.2.2. Strict government regulation for approval of drugs
3.4.3. Opportunities
3.4.3.1. Increase in R&D activities to develop T-cell therapeutics
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: T-CELL THERAPY MARKET, BY THERAPY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. CAR T-Cell therapy
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.2.4. CAR T-Cell therapy T-Cell therapy Market by Product Type
4.3. T-Cell Receptor (TCR)-Based
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: T-CELL THERAPY MARKET, BY INDICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Lymphoma
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Acute Lymphocytic Leukemia
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: T-CELL THERAPY MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Cancer Treatment Centers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
CHAPTER 7: T-CELL THERAPY MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Therapy Type
7.2.3. Market size and forecast, by Indication
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Therapy Type
7.2.5.1.3. Market size and forecast, by Indication
7.2.5.1.4. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Therapy Type
7.2.5.2.3. Market size and forecast, by Indication
7.2.5.2.4. Market size and forecast, by End User
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Therapy Type
7.3.3. Market size and forecast, by Indication
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Therapy Type
7.3.5.1.3. Market size and forecast, by Indication
7.3.5.1.4. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Therapy Type
7.3.5.2.3. Market size and forecast, by Indication
7.3.5.2.4. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Therapy Type
7.3.5.3.3. Market size and forecast, by Indication
7.3.5.3.4. Market size and forecast, by End User
7.3.5.4. Rest of Europe
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Therapy Type
7.3.5.4.3. Market size and forecast, by Indication
7.3.5.4.4. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Therapy Type
7.4.3. Market size and forecast, by Indication
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Therapy Type
7.4.5.1.3. Market size and forecast, by Indication
7.4.5.1.4. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Therapy Type
7.4.5.2.3. Market size and forecast, by Indication
7.4.5.2.4. Market size and forecast, by End User
7.4.5.3. Rest of Asia-Pacific
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Therapy Type
7.4.5.3.3. Market size and forecast, by Indication
7.4.5.3.4. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Therapy Type
7.5.3. Market size and forecast, by Indication
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Latin America
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Therapy Type
7.5.5.1.3. Market size and forecast, by Indication
7.5.5.1.4. Market size and forecast, by End User
7.5.5.2. Middle East And Africa
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Therapy Type
7.5.5.2.3. Market size and forecast, by Indication
7.5.5.2.4. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Novartis AG
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Autolus Therapeutics
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Caribou Biosciences, Inc
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Gilead Sciences, Inc.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Immunocore Ltd.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Celyad Oncology
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Key strategic moves and developments
9.7. Cartesian Therapeutics, Inc.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.8. Johnson & Johnson
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Bristol-Myers Squibb Company
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Cellectis, Inc.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
LIST OF TABLES
TABLE 01. GLOBAL T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 02. T-CELL THERAPY MARKET FOR CAR T-CELL THERAPY, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GLOBAL CAR T-CELL THERAPY T-CELL THERAPY MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
TABLE 04. T-CELL THERAPY MARKET FOR T-CELL RECEPTOR (TCR)-BASED, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 06. T-CELL THERAPY MARKET FOR LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 07. T-CELL THERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2022-2032 ($MILLION)
TABLE 08. T-CELL THERAPY MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GLOBAL T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 10. T-CELL THERAPY MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. T-CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. T-CELL THERAPY MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA T-CELL THERAPY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 18. U.S. T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 19. U.S. T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 20. CANADA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 21. CANADA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 22. CANADA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. EUROPE T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 24. EUROPE T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 25. EUROPE T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. EUROPE T-CELL THERAPY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 27. GERMANY T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 28. GERMANY T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 29. GERMANY T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 30. FRANCE T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 31. FRANCE T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 32. FRANCE T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 33. UK T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 34. UK T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 35. UK T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. REST OF EUROPE T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 37. REST OF EUROPE T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 38. REST OF EUROPE T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. ASIA-PACIFIC T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 40. ASIA-PACIFIC T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 41. ASIA-PACIFIC T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 42. ASIA-PACIFIC T-CELL THERAPY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 43. JAPAN T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 44. JAPAN T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 45. JAPAN T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 46. CHINA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 47. CHINA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 48. CHINA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 49. REST OF ASIA-PACIFIC T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 50. REST OF ASIA-PACIFIC T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 51. REST OF ASIA-PACIFIC T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 52. LAMEA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 53. LAMEA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 54. LAMEA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 55. LAMEA T-CELL THERAPY MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 56. LATIN AMERICA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 57. LATIN AMERICA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 58. LATIN AMERICA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 59. MIDDLE EAST AND AFRICA T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022-2032 ($MILLION)
TABLE 60. MIDDLE EAST AND AFRICA T-CELL THERAPY MARKET, BY INDICATION, 2022-2032 ($MILLION)
TABLE 61. MIDDLE EAST AND AFRICA T-CELL THERAPY MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 62. NOVARTIS AG: KEY EXECUTIVES
TABLE 63. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 64. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 65. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 66. AUTOLUS THERAPEUTICS: KEY EXECUTIVES
TABLE 67. AUTOLUS THERAPEUTICS: COMPANY SNAPSHOT
TABLE 68. AUTOLUS THERAPEUTICS: PRODUCT SEGMENTS
TABLE 69. AUTOLUS THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 70. AUTOLUS THERAPEUTICS: KEY STRATERGIES
TABLE 71. CARIBOU BIOSCIENCES, INC: KEY EXECUTIVES
TABLE 72. CARIBOU BIOSCIENCES, INC: COMPANY SNAPSHOT
TABLE 73. CARIBOU BIOSCIENCES, INC: PRODUCT SEGMENTS
TABLE 74. CARIBOU BIOSCIENCES, INC: PRODUCT PORTFOLIO
TABLE 75. CARIBOU BIOSCIENCES, INC: KEY STRATERGIES
TABLE 76. GILEAD SCIENCES, INC.: KEY EXECUTIVES
TABLE 77. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
TABLE 78. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
TABLE 79. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
TABLE 80. GILEAD SCIENCES, INC.: KEY STRATERGIES
TABLE 81. IMMUNOCORE LTD.: KEY EXECUTIVES
TABLE 82. IMMUNOCORE LTD.: COMPANY SNAPSHOT
TABLE 83. IMMUNOCORE LTD.: PRODUCT SEGMENTS
TABLE 84. IMMUNOCORE LTD.: PRODUCT PORTFOLIO
TABLE 85. IMMUNOCORE LTD.: KEY STRATERGIES
TABLE 86. CELYAD ONCOLOGY: KEY EXECUTIVES
TABLE 87. CELYAD ONCOLOGY: COMPANY SNAPSHOT
TABLE 88. CELYAD ONCOLOGY: PRODUCT SEGMENTS
TABLE 89. CELYAD ONCOLOGY: PRODUCT PORTFOLIO
TABLE 90. CELYAD ONCOLOGY: KEY STRATERGIES
TABLE 91. CARTESIAN THERAPEUTICS, INC.: KEY EXECUTIVES
TABLE 92. CARTESIAN THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 93. CARTESIAN THERAPEUTICS, INC.: PRODUCT SEGMENTS
TABLE 94. CARTESIAN THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 95. JOHNSON & JOHNSON: KEY EXECUTIVES
TABLE 96. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 97. JOHNSON & JOHNSON: PRODUCT SEGMENTS
TABLE 98. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 99. JOHNSON & JOHNSON: KEY STRATERGIES
TABLE 100. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 101. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 102. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
TABLE 103. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 104. CELLECTIS, INC.: KEY EXECUTIVES
TABLE 105. CELLECTIS, INC.: COMPANY SNAPSHOT
TABLE 106. CELLECTIS, INC.: PRODUCT SEGMENTS
TABLE 107. CELLECTIS, INC.: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. T-CELL THERAPY MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF T-CELL THERAPY MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN T-CELL THERAPY MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW BARGAINING POWER OF BUYERS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW THREAT OF NEW ENTRANTS
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALT-CELL THERAPY MARKET
FIGURE 10. T-CELL THERAPY MARKET, BY THERAPY TYPE, 2022(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR CAR T-CELL THERAPY, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR T-CELL RECEPTOR (TCR)-BASED, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. T-CELL THERAPY MARKET, BY INDICATION, 2022(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR LYMPHOMA, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. T-CELL THERAPY MARKET, BY END USER, 2022(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF T-CELL THERAPY MARKET FOR CANCER TREATMENT CENTERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. T-CELL THERAPY MARKET BY REGION, 2022
FIGURE 21. U.S. T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
FIGURE 22. CANADA T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
FIGURE 23. GERMANY T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
FIGURE 24. FRANCE T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
FIGURE 25. UK T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
FIGURE 26. REST OF EUROPE T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
FIGURE 27. JAPAN T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
FIGURE 28. CHINA T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
FIGURE 29. REST OF ASIA-PACIFIC T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
FIGURE 30. LATIN AMERICA T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
FIGURE 31. MIDDLE EAST AND AFRICA T-CELL THERAPY MARKET, 2022-2032 ($MILLION)
FIGURE 32. TOP WINNING STRATEGIES, BY YEAR
FIGURE 33. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 34. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 35. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 36. COMPETITIVE DASHBOARD
FIGURE 37. COMPETITIVE HEATMAP: T-CELL THERAPY MARKET
FIGURE 38. TOP PLAYER POSITIONING, 2022
FIGURE 39. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 40. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 41. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 42. AUTOLUS THERAPEUTICS: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 43. CARIBOU BIOSCIENCES, INC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 44. CARIBOU BIOSCIENCES, INC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 45. GILEAD SCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 46. GILEAD SCIENCES, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 47. IMMUNOCORE LTD.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 48. IMMUNOCORE LTD.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 49. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
FIGURE 50. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 51. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 52. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
FIGURE 53. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 54. CELLECTIS, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 55. CELLECTIS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security